Albumin improves stratification in the low IPI risk patients with diffuse large B-cell lymphoma

Previous studies showed albumin at diagnosis could be used to predict outcome in patients with diffuse large B-cell lymphoma (DLBCL), but whether albumin could improve the international prognostic index (IPI) risk stratification remains unknown. Herein, we retrospectively analyzed 440 de novo DLBCL...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2020-05, Vol.111 (5), p.681-685
Hauptverfasser:	Wei, Yongqiang, Wei, Xiaolei, Huang, Weimin, Song, Jialin, Zheng, Jingxia, Zeng, Hong, Liu, Jianbo, Zhan, Minglang, Wei, Qi, Feng, Ru
Format:	Artikel
Sprache:	eng
Schlagworte:	Albumin B-cell lymphoma Biomarkers - blood Confidence intervals Diagnosis Hematology Lymphocytes B Lymphoma Lymphoma, Large B-Cell, Diffuse - diagnosis Medical prognosis Medicine Medicine & Public Health Multivariate Analysis Oncology Original Article Patients Prognosis Retrospective Studies Risk Risk analysis Risk groups Serum albumin Serum Albumin - analysis Subgroups
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Previous studies showed albumin at diagnosis could be used to predict outcome in patients with diffuse large B-cell lymphoma (DLBCL), but whether albumin could improve the international prognostic index (IPI) risk stratification remains unknown. Herein, we retrospectively analyzed 440 de novo DLBCL patients in this study. The cutoff value of albumin was 39.2 g/L. Patients with high serum albumin showed superior OS and PFS ( p = 0.002 and p
ISSN:	0925-5710 1865-3774
DOI:	10.1007/s12185-020-02818-9